JP2021527062A5 - - Google Patents
Info
- Publication number
- JP2021527062A5 JP2021527062A5 JP2020567973A JP2020567973A JP2021527062A5 JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5 JP 2020567973 A JP2020567973 A JP 2020567973A JP 2020567973 A JP2020567973 A JP 2020567973A JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- level
- complement factor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024088364A JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682013P | 2018-06-07 | 2018-06-07 | |
| US62/682,013 | 2018-06-07 | ||
| PCT/US2019/035758 WO2019236820A1 (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Division JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527062A JP2021527062A (ja) | 2021-10-11 |
| JP2021527062A5 true JP2021527062A5 (enExample) | 2022-06-13 |
Family
ID=68764799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567973A Pending JP2021527062A (ja) | 2018-06-07 | 2019-06-06 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11191756B2 (enExample) |
| EP (1) | EP3801519A4 (enExample) |
| JP (2) | JP2021527062A (enExample) |
| KR (2) | KR20210018906A (enExample) |
| CN (1) | CN112423752A (enExample) |
| AU (1) | AU2019282327B2 (enExample) |
| BR (1) | BR112020024842A2 (enExample) |
| CA (1) | CA3102403A1 (enExample) |
| CL (1) | CL2020003171A1 (enExample) |
| IL (1) | IL279188B2 (enExample) |
| MA (1) | MA52808A (enExample) |
| MX (1) | MX2020013166A (enExample) |
| SG (1) | SG11202011961YA (enExample) |
| WO (1) | WO2019236820A1 (enExample) |
| ZA (1) | ZA202007615B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| CN113164403A (zh) | 2018-11-30 | 2021-07-23 | 凯莫森特里克斯股份有限公司 | 胶囊制剂 |
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| WO2026157730A1 (en) * | 2025-01-21 | 2026-07-30 | Metagone Biotech Inc. | Compositions and methods for treatment of macular degeneration and geographic atrophy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| CN101611008A (zh) * | 2006-12-22 | 2009-12-23 | 恩希赛弗制药公司 | C3a受体调节剂及其使用方法 |
| CA2714296A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| JP5819730B2 (ja) | 2008-12-22 | 2015-11-24 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| JP6898229B6 (ja) | 2014-09-29 | 2021-07-28 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト製造における方法及び中間体 |
| EP3283889B1 (en) | 2015-04-17 | 2020-02-26 | Euroimmun Medizinische Labordiagnostika AG | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| SG11201808625QA (en) | 2016-04-04 | 2018-10-30 | Chemocentryx Inc | SOLUBLE C5aR ANTAGONISTS |
| KR20200109297A (ko) | 2017-10-31 | 2020-09-22 | 케모센트릭스, 인크. | 소변 sCD163의 C5aR 억제제 감소 |
| JP2021527062A (ja) | 2018-06-07 | 2021-10-11 | ケモセントリックス，インコーポレイティド | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
-
2019
- 2019-06-06 JP JP2020567973A patent/JP2021527062A/ja active Pending
- 2019-06-06 IL IL279188A patent/IL279188B2/en unknown
- 2019-06-06 CA CA3102403A patent/CA3102403A1/en active Pending
- 2019-06-06 KR KR1020217000253A patent/KR20210018906A/ko not_active Ceased
- 2019-06-06 MA MA052808A patent/MA52808A/fr unknown
- 2019-06-06 US US16/433,487 patent/US11191756B2/en active Active
- 2019-06-06 SG SG11202011961YA patent/SG11202011961YA/en unknown
- 2019-06-06 WO PCT/US2019/035758 patent/WO2019236820A1/en not_active Ceased
- 2019-06-06 MX MX2020013166A patent/MX2020013166A/es unknown
- 2019-06-06 BR BR112020024842-8A patent/BR112020024842A2/pt unknown
- 2019-06-06 EP EP19814841.3A patent/EP3801519A4/en active Pending
- 2019-06-06 AU AU2019282327A patent/AU2019282327B2/en active Active
- 2019-06-06 KR KR1020267004102A patent/KR20260027358A/ko active Pending
- 2019-06-06 CN CN201980038855.4A patent/CN112423752A/zh active Pending
-
2020
- 2020-12-04 CL CL2020003171A patent/CL2020003171A1/es unknown
- 2020-12-07 ZA ZA2020/07615A patent/ZA202007615B/en unknown
-
2021
- 2021-11-04 US US17/519,266 patent/US12350263B2/en active Active
-
2024
- 2024-05-30 JP JP2024088364A patent/JP2024114706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516646A5 (enExample) | ||
| JP2023078341A5 (enExample) | ||
| JP2020517696A5 (enExample) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2019529581A5 (enExample) | ||
| JP2013521303A5 (enExample) | ||
| JP2023076465A5 (enExample) | ||
| JP2022527398A5 (enExample) | ||
| JP2017525713A5 (enExample) | ||
| JP2022062170A5 (enExample) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2021534129A5 (enExample) | ||
| JP2023530264A5 (enExample) | ||
| JP2018065829A5 (enExample) | ||
| JP2023549849A5 (enExample) | ||
| JP2022517902A5 (enExample) | ||
| JP2019524820A5 (enExample) | ||
| MX2020013166A (es) | Dosificación y efecto del antagonista de c5a con la vasculitis asociada con anca. | |
| JP2022546456A5 (enExample) | ||
| JP2019524889A5 (enExample) | ||
| JP2025509278A5 (enExample) | ||
| JP2024512558A5 (enExample) | ||
| JP2021521227A5 (enExample) | ||
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease |